Related to Industry-Academic Consortium Set Up to Bolster Schizophrenia and Depression R&D

• BMS Shells Out $400M to Extend Revenue-Sharing Period with Otsuka for Abilify
  
• GSK Divests U.S. Rights for Depression Drug to Biovail for $510M
  
• Researchers Find Biological Link Between Tumors and Depression
  
• Clinical Data’s Depression Therapy Shows Positive Phase III Results
  
• Investigators Identify SNPs Associated with Predisposition to Schizophrenia
  
• miRNA Mutations on X-Chromosome Linked to Schizophrenia
  
• Inadequate Levels of Brain Protein Leads to Blockage in Schizophrenic Brain
  
• Gene Deletion Associated with Autistic and Schizophrenic Behaviors in Mice
  
• Novartis Shells Out $200M for U.S. and Canadian Rights to Vanda’s FDA-Approved Schizophrenia Drug
  
• AstraZeneca Provides $200M Up Front to Develop Targacept’s Late-Stage Candidate for Depression
  
• Virginia Commonwealth University Obtains $4.5M to Identify Schizophrenia Markers
  
• Roche Taps Psynova to Develop Schizophrenia Companion Diagnostic
  
• AstraZeneca’s Antidepressant Gets FDA Nod for Label Expansion
  
• Investigators Create Schizophrenia Mouse Model
  
• FDA Asks IntelGenx to Fine-Tune CMO and Food Effect Details for Antidepressant Approval
  
• Biovail Ponies Up $40M for North American Rights to Inhaled Version of Therapy for Schizophrenia Symptoms
  
• Marco Polo Takes Over Biocortech’s Antidepressant for Treatment-Resistant Disease
  
• AstraZeneca to Pay $520M Settlement in Seroquel Lawsuit
  
• Aestus and Eisai Ally to Develop Treatments for Psychiatric Disorders
  
• Euthymics Raises $24M to Progress Phase II/III-Stage Antidepressant